Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004;93:1124 1129. doi: 10.1016/j.amjcard.2004.01.039. 272. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Py r l K. The effects of simvastatin on the incidence of heart failure in pa- tients with coronary heart disease [published correction appears in J Card Fail. 1998;4:367]. J Card Fail. 1997;3:249 254. Bozkurt et al 273. Kjekshus J, Apetrei E, Barrios V, B hm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, J nosi A, Kamensk G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older pa- tients with systolic heart failure. N Engl J Med. 2007;357:2248 2261. doi: 10.1056/NEJMoa0706201. 274. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI- HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231 1239. doi: 10.1016/S0140-6736(08)61240-4. 275. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA. AHA/ACCF secondary pre- vention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation [published correction appears in Circulation. 2015;131:e408]. Circulation. 2011;124:2458 2473. doi: 10.1161/CIR.0b013e318235eb4d. 276. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 